Elevation Oncology launches with $32.5 million Series A, gives new life to former Merrimack program

Almost two years ago, Merrimack’s high-profile seribantumab program flopped in a trial that attempted to treat non-small cell lung cancer in combination with another drug. Now, that program is getting a second chance.